A new type of a US Medicare prescription drug plan will cap insulin costs at $35 per month for people who have diabetes. But it doesn't change actual prices.
Taxpayers Paid to Develop Remdesivir but will Have no Say When Gilead Sets the Price Opens in a new window)Critics say government deserves more credit for tens of millions in public money spent to develop coronavirus treatment.
The Motivation, Potential, and Limitations of a New Payment Model
This diagram contains an aggregation of publicly available information (from validated sources) on the development of treatments and vaccines for COVID-19.